Cypralis is focused on the discovery and development of highly innovative therapeutics for the modulation of peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets known to be involved in many acute and chronic diseases. More…

Pipeline

Cypralis’ pipeline includes novel medicines being developed for degenerative diseases such as Liver Disease, Acute Tissue Injury and Inflammation.

Research Portfolio

Technology

Cypralis is focused on the discovery and development of highly innovative therapeutics for the modulation of peptidyl-prolyl isomerases known as PPIases, a large druggable family of protein targets involved in many acute and chronic diseases.

Read more

Contact Us

Cypralis is seeking to establish collaborations with pharmaceutical and biotech companies to develop PPIase inhibitors for a number of diseases. Please contact us to explore the opportunities.

+44 (0)1277 367 020